What is GPCR's current stock price?

GPCR (Structure Therapeutics Inc.) is currently trading at $39.43 with a market cap of $2.27B.

What sector is Structure Therapeutics Inc. in?

Structure Therapeutics Inc. (GPCR) operates in the Healthcare sector, specifically in the Biotechnology industry.

Is GPCR a good stock to buy?

Analysts have a Buy consensus on GPCR with a price target of $114.75. Check our detailed analysis for valuation, financials, and insider activity.

InvestLog

GPCR Structure Therapeutics Inc.

Healthcare

$39.43+0.00%OpenMarket Cap: $2.27B

As of 2026-05-26

Valuation

View Details

P/E (TTM)

—

PEG

—

P/B

1.96

P/S

0.00

EV/EBITDA

-10.22

DCF Value

$13.18

FCF Yield

-7.1%

Div Yield

0.0%

Margins & Returns

Gross Margin

0.0%

Operating Margin

0.0%

Net Margin

0.0%

ROE

-15.1%

ROA

-11.3%

ROIC

-14.4%

Financials

View All

Period	Revenue	Net Income	EPS
Q1 null	$0.00	$-76.2M	$—
Q4 null	$0.00	$33.0M	$—
FY null	$0.00	$-141.2M	$—
Q3 null	$0.00	$-65.7M	$—

Analyst Ratings

View All

Consensus

Buy

Target (Consensus)

$114.75

Target (Median)

$113.50

Target Range

$90.00 - $145.00

4 Strong Buy12 Buy1 Hold0 Sell0 Strong Sell

HC Wainwright & Co.Buy

2026-03-16

CitizensMarket Outperform

2026-02-27

JP MorganOverweight

2026-01-22

GuggenheimBuy

2026-01-20

HC Wainwright & Co.Buy

2025-12-19

Trading Activity

Insider Trades

View All

Lang Matthewofficer: COO & GC

SellThu Apr 23

Lang Matthewofficer: COO & GC

SellThu Apr 23

Lang Matthew

SellThu Apr 23

FMR LLC10 percent owner, other: See Remark 1

SellThu Apr 16

FMR LLC10 percent owner, other: See Remark 1

SellThu Apr 16

Company Info

Sector

Healthcare

Industry

Biotechnology

Country

Exchange

—

Beta

-1.39

Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. Its lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity. The company is also developing oral small molecule therapeutics targeting other GPCRs for the treatment of pulmonary and cardiovascular diseases, including ANPA-0073, a biased agonist, targeting apelin receptor, a GPCR that has been implicated in idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension; and LTSE-2578, an investigational oral small molecule lysophosphatidic acid 1 receptor antagonist for the treatment of IPF. The company was formerly known as ShouTi Inc. Structure Therapeutics Inc. was founded in 2016 and is headquartered in South San Francisco, California.

Peers